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WhaT is cOmparaTiVe eFFecTiVeness research....
and WhY dO iT?
Comparative effectiveness research (CER) aids clinicians 
faced with medical decision making by identifying the best 
strategies among a variety of available preventive, diagnos-
tic, and treatment options. Differing from early-phase clini-
cal trials—in which an intervention is compared with a pla-
cebo and assessed for efficacy—the goal of CER is to dis-
criminate among clinical interventions on the basis of clini-
cal effectiveness, cost-effectiveness, adverse effects, or other 
distinguishing factors.
As part of the American Recovery and Reinvestment Act 
of 2009, the US government allocated $1.1 billion for the 
funding of CER with two primary aims: “(1) to conduct, 
support, or synthesize research that compares the clinical 
outcomes, effectiveness, and appropriateness of items, ser-
vices, and procedures that are used to prevent, diagnose, or 
treat diseases, disorders, and other health conditions; and 
(2) encourage the development and use of clinical regis-
tries, clinical data networks, and other forms of electronic 
health data that can be used to generate or obtain outcomes 
data” (Department of Health and Human Services, http://
www.hhs.gov/recovery/programs/cer/index.html, accessed 
15 September 2012). One motivation behind the funding of 
CER is stimulating the delivery of higher-quality health care 
in a more cost-effective manner. Through well-designed and 
executed studies, CER has the potential to greatly enhance 
the practice of evidence-based dermatology (Williams, 
2011). Common methodological approaches to conduct-
ing CER include randomized controlled trials and system-
atic reviews. This article will review recent examples of CER 
study designs in the dermatology literature as well as statisti-
cal analyses used to interpret such designs. 
meThOds OF cer 
CER may be conducted through a variety of study methods. 
One approach is to perform a systematic review of exist-
ing literature addressing one clinical question. Systematic 
reviews are detailed analyses and evaluations of all the pub-
lished data on a specific topic to date. The aim is to draw 
conclusions from the large volume of data that are assessed 
across multiple published studies to answer the question 
at hand. These reviews offer the opportunity to conduct 
statistical analyses of aggregated data—a so-called meta-
analysis—to gain broader insights that any one study would 
not have been large enough to assess. The use of patient reg-
istries built around specific clinical conditions facilitates such 
research by aggregating data for further study and analysis.
Another approach to CER is to design a randomized con-
trolled trial to answer a specific clinical question. Studies that 
randomize patients to receive one commonly used medica-
tion versus another constitute a fundamental exercise of CER. 
Under this method, participants are randomly assigned to 
two or more groups that differ only on the basis of exposure 
to the study variable addressing the clinical question (namely, 
the medications, procedures, or diagnostic tools being com-
pared). The groups are followed for predetermined outcomes 
of interest to address the question at hand, and the results of 
WHAT COMPARATIVE EFFECTIVENESS 
RESEARCH DOES
•  Aims to discriminate among clinical interventions 
on the basis of clinical effectiveness, cost-
effectiveness, adverse effects, or other 
distinguishing factors.
•  Answers questions from the patient and provider 
perspective of “which therapy is better?”
•  Provide insights for future health-care policy and 
clinical decision making.
LIMITATIONS 
•  Conducting randomized trials to provide the best 
evidence is often expensive, labor intensive, and 
time-consuming.
•  Rare conditions or disease states may not have 
sufficient individuals available for enrolling in such 
studies.
•  Interpretation of studies is contingent upon 
appropriate study design and methodology.
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in the same study, using the same study design, double blind, 
with efficacy measured using the same disease severity indi-
ces. Surgical therapeutics may also be compared for effec-
tiveness via randomized controlled trials, as has been done 
to assess surgical excision versus Mohs micrographic surgery 
for basal-cell carcinoma of the face (Mosterd et al., 2008). 
“Real-world” studies in which participants are patients treat-
ed in private-practice as well as academic settings, using on-
label medications to manage the same disease process, are 
also considered within the scope of CER. The study design is 
cross-sectional, in which patients with the same clinical con-
dition are treated with a range of therapeutic interventions 
and assessed for clinical response in a nonrandomized man-
ner, as has been done with a variety of psoriasis treatments 
(Gelfand et al., 2012). 
A large comparative effectiveness study published in the 
Journal of Investigative Dermatology in 2009 assessed two 
treatment regimens of the same steroid, clobetasol propio-
nate, for disease control and event-free survival in patients 
with bullous pemphigoid (Joly et al., 2009). A total of 312 
patients with moderate or extensive bullous pemphigoid 
were randomized to treatment with either high-dose clo-
betasol (40 g/day) or low-dose clobetasol (10–30 g/day). An 
important methodological component of any such trial is 
the a priori estimation of sample size, which calculates the 
number of subjects needed to detect significant differences in 
effects between interventions. The 2009 study was designed 
to have 80% power to detect a 33% difference in event-
free survival between the two groups, with a one-sided log-
rank test and type I error of 5%. Simply put, the statistical 
power of the study is the probability of finding a significant 
difference that does exist between the two groups; increas-
ing the power of the study while holding other parameters 
equal will increase the number of experimental samples 
needed to reach the same level of significance. A type I error 
occurs when a difference between the two groups is claimed, 
although one does not actually exist. The probability of a 
type I error is known as α. Decreasing α—and thus reducing 
the probability of making such an error—while holding other 
parameters equal will require a larger sample size.
The bullous pemphigoid study cited above used the log-
rank test for analysis of event-free and disease-free survival 
between patients in the two treatment groups (Figure 1). This 
test is used to assess differences between populations in the 
probability of an event over time, such as death or disease 
recurrence, and is often used for comparisons of survival 
between experimental groups (Bland and Altman, 2004). 
Such data are routinely plotted in Kaplan–Meier curves, 
which display time on the x-axis and percentage of surviving 
or unaffected individuals on the y-axis. Joly and colleagues 
reported no significant difference in overall event-free sur-
vival (patients unaffected by life-threatening adverse events 
or death) between the two treatment groups (P value = 0.95, 
Figure 1a). Significantly fewer side effects were seen in the 
lower-dose group. However, there was a significantly higher 
rate of disease relapse in subjects given the lower dose of 
steroids (P value = 0.012, Figure 1b). The authors concluded 
that the lower-steroid regimen demonstrated comparable 
the two groups are compared by statistical analyses. Patients 
may be randomized at the individual level, or whole groups 
of patients may be randomized to particular interventions 
in the “cluster randomized” approach. Although often con-
sidered the gold standard for clinical research, randomized 
controlled trials are expensive, labor intensive, and time-
consuming and may be particularly difficult to conduct for 
studying rare diseases.
cer in dermaTOlOGY: TherapeuTics
Several common dermatologic conditions may be initially 
managed with a variety of medication classes. In a patient 
presenting with moderate acne, topical macrolide antibiot-
ics, topical retinoids, topical benzoyl peroxide, and systemic 
antibiotics may all be considered part of the initial therapeu-
tic regimen; similarly, for a patient presenting with mild to 
moderate atopic dermatitis of the face, topical corticosteroids 
or topical calcineurin inhibitors may be considered. Within 
each of these broad classes of medications, several treatment 
choices exist. Large randomized trials comparing multiple 
treatments head to head for a single condition—such as acne 
(Ozolins et al., 2004) or head lice (Chosidow et al., 2010)—
offer important lessons for therapeutic agent selection by 
demonstrating significant differences in clinical effectiveness 
across treatments. The important point is that study partici-
pants must be randomly assigned to two or more treatments 
Figure 1. Kaplan–meier curves. These curves demonstrate event-free and 
disease-free survival in patients treated with different topical steroid regimens 
for bullous pemphigoid. From Joly et al., 2009.
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clinical effectiveness with fewer side effects and lower over-
all costs that outweigh the slightly higher rate of relapse, a 
powerful lesson for both patients and their clinicians going 
forward. When addressing multiple treatment interventions 
in CER, selecting the appropriate statistical model and test 
is critical for a valid interpretation of the results and to limit 
research wastage caused by flawed designs or methodology 
(Williams and Delavalle, 2012).
cer in dermaTOlOGY: diaGnOsTic TOOls and 
healTh-care TechnOlOGies
As a field in which clinical activities span physical diagnosis, 
medical and surgical treatments, long-term patient follow-
up, and population health, clinical dermatology integrates 
several technologies into its routine practice. In addition to 
comparisons of pharmacologic treatments, CER can also be 
used to assess diagnostic instruments and other health-care 
technologies used in the practice of dermatology. There is 
a great need to develop outcomes in dermatology that are 
valid and reliably measure the diagnosis of a disease (e.g., 
screening questionnaires used in large epidemiology studies 
or diagnostic criteria used during a physical exam), disease 
severity (e.g., the Eczema Area and Severity Index), subphe-
notypes of disease (e.g., localized alopecia areata versus alo-
pecia areata totalis), and health-related quality-of-life indi-
ces. Beyond development of indices and outcomes, CER is 
needed to better assess the use of measures in various set-
tings (e.g., clinic vs. clinical trial). For example, efforts have 
begun to systematically review the process by which skin 
cancer is diagnosed by specialist and nonspecialist clinicians 
and to better understand the clinical impact of noninvasive 
technologies such as dermoscopy and photography on skin 
cancer diagnosis (Parsons et al., 2011).
Another recent study compared the Skindex-29 with the 
Skindex-17, two health-related quality-of-life survey instru-
ments that quantify the patient burden of dermatologic dis-
ease (Sampogna et al., 2012). The Skindex-17 consists of a 
subset of questions that are derived from those in the longer 
29-item questionnaire. Data from 2,487 patients who com-
pleted Skindex-29 surveys administered in a single institution 
were used to compute corresponding Skindex-17 scores. The 
mean values from these two sets of scores were then com-
pared (Table 1). Sampogna and colleagues used intraclass 
correlation coefficients (ICCs) to compare the scores on the 
two questionnaires. The ICC is a statistical test used to cal-
culate the reproducibility of measurements (or scores) of two 
different instruments measuring the same entity. The correla-
tion coefficient is reported from 0 to 1. A high ICC represents 
a high degree of agreement between the scoring instruments. 
The two Skindex scores were found to have an ICC of 0.957 
for questions regarding symptoms and an ICC of 0.94 for 
questions regarding psychosocial impact of disease. The high 
level of concordance observed between the instruments led 
the researchers to suggest that the shorter questionnaire may 
be effectively used to measure health-related quality of life, 
thereby reducing challenges associated with a longer survey, 
such as great respondent burden. Such research adds mean-
ingful data by addressing the very metrics by which we assess 
dermatologic disease and also inspires further investigation 
of the effectiveness of our research tools and methodologies.
FuTure direcTiOns FOr cer in dermaTOlOGY
The current attention focused on CER by federal and inter-
national agencies looking to enhance the quality of medi-
cal-care delivery argues strongly for increased CER efforts 
within dermatology. Identifying meaningful future direc-
tions for such research should help translate into better, 
Table 1. Mean values of the Sk-29 and of the Sk-17
scores and their ICC in different dermatological
conditions
Symptoms Psychosocial
n Sk-29 Sk-17 ICC Sk-29 Sk-17 ICC
Acne 193 33.2 37.3 0.939 32.1 33.6 0.927
Alopecia androgenetic 77 13.0 15.5 0.950 16.3 16.4 0.901
Alopecia areata 52 9.9 9.8 0.948 22.0 23.4 0.929
Bacterial infections 53 40.2 44.6 0.910 26.0 26.0 0.907
Balanitis 25 33.6 37.2 0.889 24.0 27.2 0.951
Benign skin neoplasias 175 13.9 15.7 0.930 10.0 8.2 0.907
Dermatitis 249 45.1 50.2 0.942 25.9 26.6 0.937
Hair loss 27 17.8 21.1 0.968 22.3 21.2 0.941
Lichen planus 32 34.2 38.4 0.942 20.3 16.8 0.914
Mycoses 116 28.1 31.8 0.954 17.4 17.0 0.925
Nail conditions 38 17.4 20.0 0.964 17.0 15.0 0.862
Nevi 306 10.3 12.3 0.925 8.7 6.7 0.911
Non-melanoma skin
cancers
79 18.2 19.6 0.930 12.8 9.2 0.890
Pemphigus/bullous
diseases
17 44.2 46.0 0.968 38.3 37.0 0.983
Pityriasis rosea 29 27.6 31.1 0.882 21.0 19.6 0.920
Pruritus 54 49.2 53.7 0.903 29.4 24.8 0.953
Psoriasis 220 47.9 54.2 0.946 32.5 33.0 0.941
Rosacea 60 33.3 33.2 0.951 26.2 26.1 0.953
Scabies and other
ectoparasitic infections
34 51.5 57.0 0.942 40.7 40.8 0.935
249.03.332.33179.02.331.9291sracS
Scleroderma/
connective tissue
disorders
49 35.2 40.0 0.954 28.5 29.2 0.953
Seborrheic dermatitis 85 33.5 36.3 0.942 19.1 20.2 0.906
Urticaria 29 44.8 44.8 0.908 27.5 28.4 0.921
Viral infections 68 19.9 21.1 0.946 18.0 16.9 0.939
Vitiligo and other
pigmentation disorders
54 12.0 11.3 0.916 19.5 20.3 0.921
Other dermatoses 60 39.1 41.3 0.948 29.0 30.3 0.920
Missing and other
diagnoses
287 28.2 29.6 0.956 21.2 20.9 0.929
Overall 2,487 28.9 31.9 0.957 21.6 21.1 0.940
Abbreviations: ICC, intraclass correlation coefficient; Sk-17, Skindex-17;
Sk-29, Skindex-29.
From Sampogna et al., 2012.
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evidence-driven, more effective patient care. Surveys of 
clinicians actively engaged in the treatment of patients with 
psoriasis have identified particular therapeutic interventions 
that these practitioners would like to see compared in future 
CER studies (Wan et al., 2012), providing guidance for addi-
tional work in the field. Recent studies comparing electron-
ic-health and teledermatology visits for the management of 
chronic conditions such as acne (Watson et al., 2010) and 
atopic dermatitis (van Os-Medendorp et al., 2012) begin to 
address the value of technology-based care delivery in the 
practice of clinical dermatology. With proper planning and 
analysis, CER studies represent a powerful addition to the 
investigative dermatologist’s toolkit for answering an array 
of complex questions. Current attention to better, more 
efficient, and lower-cost health-care delivery in the United 
States may be the burning platform for CER. With increasing 
demand for reducing variation and clinical process improve-
ment, CER may finally receive the attention required to pro-
pel the next group of large studies. The ultimate challenge for 
the practicing clinician will be to translate these studies into 
better care for patients with dermatologic disease. 
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QUESTIONS
1.  study designs used for comparative effectiveness 
research include which of the following?
A. Systematic review.
B. Randomized controlled trial.
C. Cross-sectional study.
D. All of the above.
2.  differences in survival between two treatment 
groups are best compared using which of the 
following statistical methods?
A. Paired t test.
B. Log-rank test.
C. ANOVA.
D. Fisher’s exact test.
3.  The icc representing the best degree of agreement 
between two diagnostic tools among the following is:
A. <0.01.
B. 0.05.
C. 0.50.
D. 0.95.
Answers to the questions and an opportunity to comment on the 
article are available on our blog: http://blogs.nature.com/jid_jottings/.
